Current and Resolved Drug Shortages and Discontinuations Reported to FDA
Report a Drug Shortage |
FAQ |
Background Info |
Get Email Alerts |
Download Current Drug Shortages |
Contact Us
Start Over | Back to Previous Screen
Lisdexamfetamine Dimesylate Capsule
Status: Currently in Shortage
»Date first posted:
07/14/2023
»Therapeutic Categories: Psychiatry
Alvogen (Revised 04/17/2024)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Capsule, 10 mg (NDC 47781-562-01) | Limited Availability | Shortage of an active ingredient | |
| Capsule, 20 mg (NDC 47781-563-01) | Unavailable | Shortage of an active ingredient | |
| Capsule, 30 mg (NDC 47781-564-01) | Unavailable | Shortage of an active ingredient | |
| Capsule, 40 mg (NDC 47781-565-01) | Unavailable | Resupply End of April 2024 | Shortage of an active ingredient |
| Capsule, 50 mg (NDC 47781-566-01) | Unavailable | Resupply End of April 2024 | Shortage of an active ingredient |
| Capsule, 60 mg (NDC 47781-567-01) | Unavailable | DEA Quota | Shortage of an active ingredient |
| Capsule, 70 mg (NDC 47781-568-01) | Limited Availability | Shortage of an active ingredient |
Amneal Pharmaceuticals (Reverified 02/09/2024)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Capsule, 20 mg (NDC 65162-023-09) | Unavailable | Shortage of an active ingredient | |
| Capsule, 30 mg (NDC 65162-024-09) | Unavailable | Shortage of an active ingredient | |
| Capsule, 40 mg (NDC 65162-025-09) | Unavailable | Shortage of an active ingredient | |
| Capsule, 50 mg (NDC 65162-026-09) | Unavailable | Shortage of an active ingredient | |
| Capsule, 60 mg (NDC 65162-027-09) | Unavailable | Shortage of an active ingredient | |
| Capsule, 70 mg (NDC 65162-028-09) | Unavailable | Shortage of an active ingredient |
Apotex Corp. (Reverified 04/23/2024)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Capsule, 10 mg (NDC 60505-4739-1) | Unavailable | Next resupply to be determined. | Shortage of an active ingredient |
| Capsule, 20 mg (NDC 60505-4740-1) | Limited Availability | Next resupply to be determined. | Shortage of an active ingredient |
| Capsule, 30 mg (NDC 60505-4741-1) | Unavailable | Next resupply to be determined. | Shortage of an active ingredient |
| Capsule, 40 mg (NDC 60505-4742-1) | Unavailable | Next resupply to be determined. | Shortage of an active ingredient |
| Capsule, 50 mg (NDC 60505-4743-1) | Limited Availability | Next resupply to be determined. | Shortage of an active ingredient |
| Capsule, 60 mg (NDC 60505-4744-1) | Limited Availability | Next resupply to be determined. | Shortage of an active ingredient |
| Capsule, 70 mg (NDC 60505-4745-1) | Limited Availability | Next resupply to be determined. | Shortage of an active ingredient |
Hikma Pharmaceuticals USA, Inc. (Reverified 04/16/2024)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Capsule, 20 mg (NDC 0054-0370-25) | Limited Availability | Available on allocation | Shortage of an active ingredient |
| Capsule, 30 mg (NDC 0054-0371-25) | Limited Availability | Available on allocation | Shortage of an active ingredient |
| Capsule, 40 mg (NDC 0054-0372-25) | Limited Availability | Available on allocation | Shortage of an active ingredient |
| Capsule, 50 mg (NDC 0054-0373-25) | Limited Availability | Available on allocation | Shortage of an active ingredient |
| Capsule, 60 mg (NDC 0054-0374-25) | Limited Availability | Available on allocation | Shortage of an active ingredient |
| Capsule, 70 mg (NDC 0054-0375-25) | Limited Availability | Available on allocation | Shortage of an active ingredient |
Lannett Company, Inc. (Reverified 04/15/2024)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Capsule, 10 mg (NDC 0527-4661-37) | Limited Availability | Allocating limited inventory | Shortage of an active ingredient |
| Capsule, 20 mg (NDC 0527-4662-37) | Unavailable | Shortage of an active ingredient | |
| Capsule, 30 mg (NDC 0527-4663-37) | Unavailable | Shortage of an active ingredient | |
| Capsule, 40 mg (NDC 0527-4664-37) | Unavailable | Shortage of an active ingredient | |
| Capsule, 50 mg (NDC 0527-4665-37) | Unavailable | Shortage of an active ingredient | |
| Capsule, 60 mg (NDC 0527-4666-37) | Unavailable | Shortage of an active ingredient | |
| Capsule, 70 mg (NDC 0527-4667-37) | Unavailable | Shortage of an active ingredient |
Mylan Pharmaceuticals Inc., a Viatris Company (Reverified 04/16/2024)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Capsule, 10 mg (NDC 0378-6854-77) | Limited Availability | Allocating limited inventory | Shortage of an active ingredient |
| Capsule, 20 mg (NDC 0378-6855-77) | Limited Availability | Allocating limited inventory | Shortage of an active ingredient |
| Capsule, 30 mg (NDC 0378-6856-77) | Limited Availability | Allocating limited inventory | Shortage of an active ingredient |
| Capsule, 40 mg (NDC 0378-6857-77) | Limited Availability | Allocating limited inventory | Shortage of an active ingredient |
| Capsule, 50 mg (NDC 0378-6858-77) | Limited Availability | Allocating limited inventory | Shortage of an active ingredient |
| Capsule, 60 mg (NDC 0378-6859-77) | Limited Availability | Allocating limited inventory | Shortage of an active ingredient |
| Capsule, 70 mg (NDC 0378-6860-77) | Limited Availability | Allocating limited inventory | Shortage of an active ingredient |
Rhodes Pharmaceuticals L.P. (Revised 04/22/2024)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Capsule, 10 mg (NDC 42858-161-01) | Unavailable | Shortage of an active ingredient | |
| Capsule, 20 mg (NDC 42858-162-01) | Unavailable | Shortage of an active ingredient | |
| Capsule, 30 mg (NDC 42858-163-01) | Unavailable | Shortage of an active ingredient | |
| Capsule, 40 mg (NDC 42858-164-01) | Unavailable | Shortage of an active ingredient | |
| Capsule, 60 mg (NDC 42858-166-01) | Unavailable | Shortage of an active ingredient | |
| Capsule, 50 mg (NDC 42858-165-01) | Unavailable | Shortage of an active ingredient | |
| Capsule, 70 mg (NDC 42858-167-01) | Unavailable | Shortage of an active ingredient |
Solco Healthcare US, LLC (Reverified 04/01/2024)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Capsule, 10 mg (NDC 43547-602-10) | Limited Availability | On allocation | Shortage of an active ingredient |
| Capsule, 20 mg (NDC 43547-603-10) | Limited Availability | On allocation | Shortage of an active ingredient |
| Capsule, 30 mg (NDC 43547-604-10) | Limited Availability | On allocation | Shortage of an active ingredient |
| Capsule, 40 mg (NDC 43547-605-10) | Limited Availability | On allocation | Shortage of an active ingredient |
| Capsule, 50 mg (NDC 43547-606-10) | Limited Availability | On allocation | Shortage of an active ingredient |
| Capsule, 60 mg (NDC 43547-607-10) | Limited Availability | On allocation | Shortage of an active ingredient |
| Capsule, 70 mg (NDC 43547-608-10) | Limited Availability | On allocation | Shortage of an active ingredient |
SpecGx LLC (Revised 04/03/2024)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Capsule, 10 mg (NDC 0406-5111-01) | Limited Availability | Available for primary customers only; Backorder expected in June with extended backorder once inventory depletes. | Shortage of an active ingredient |
| Capsule, 20 mg (NDC 0406-5112-01) | Limited Availability | Next release 3/15. Extended backorder expected once inventory depletes, expected in June. | Shortage of an active ingredient |
| Capsule, 30 mg (NDC 0406-5113-01) | Limited Availability | Next release 3/15. Extended backorder expected once inventory depletes, expected in June. | Shortage of an active ingredient |
| Capsule, 40 mg (NDC 0406-5114-01) | Limited Availability | Extended backorder expected once inventory depletes, expected in April - Same month as release | Shortage of an active ingredient |
| Capsule, 50 mg (NDC 0406-5115-01) | Limited Availability | Extended backorder expected once inventory depletes, expected in April - Same month as release | Shortage of an active ingredient |
| Capsule, 60 mg (NDC 0406-5116-01) | Limited Availability | Next release 3/15. Extended backorder expected once inventory depletes, expected in June. | Shortage of an active ingredient |
| Capsule, 70 mg (NDC 0406-5117-01) | Limited Availability | Shortage of an active ingredient |
Sun Pharmaceutical Industries, Inc. (Revised 03/15/2024)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Capsule, 10 mg (NDC 57664-046-88) | Unavailable | Not available. Return to stock possible in mid of May 2024 | Shortage of an active ingredient |
| Capsule, 30 mg (NDC 57664-048-88) | Unavailable | Not available. Return to stock possible in mid of May 2024 | Shortage of an active ingredient |
| Capsule, 30 mg (NDC 57664-048-88) | Unavailable | Not available. Return to stock possible in mid of May 2024 | Shortage of an active ingredient |
| Capsule, 40 mg (NDC 57664-049-88) | Unavailable | Not available. Return to stock possible in mid of May 2024 | Shortage of an active ingredient |
| Capsule, 50 mg (NDC 57664-050-88) | Unavailable | Not available. Return to stock possible in mid of May 2024 | Shortage of an active ingredient |
| Capsule, 60 mg (NDC 57664-051-88) | Unavailable | Not available. Return to stock possible in mid of May 2024 | Shortage of an active ingredient |
| Capsule, 70 mg (NDC 57664-052-88) | Unavailable | Not available. Return to stock possible in mid of May 2024 | Shortage of an active ingredient |
Takeda Pharmaceuticals USA Inc. (Reverified 04/15/2024)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Vyvanse, Capsule, 10 mg (NDC 59417-101-10) | Available | ||
| Vyvanse, Capsule, 20 mg (NDC 59417-102-10) | Available | ||
| Vyvanse, Capsule, 30 mg (NDC 59417-103-10) | Available | ||
| Vyvanse, Capsule, 40 mg (NDC 59417-104-10) | Available | ||
| Vyvanse, Capsule, 50 mg (NDC 59417-105-10) | Available | ||
| Vyvanse, Capsule, 60 mg (NDC 59417-106-10) | Available | ||
| Vyvanse, Capsule, 70 mg (NDC 59417-107-10) | Available |